Abstract
Rheumatoid arthritis (RA), as an persistent autoimmune condition, it is known for causing persistent synovitis, gradual deterioration of cartilage and bone, ultimately resulting in disability and widespread inflammation. Until now, the onset and development mechanisms of RA remain elusive, although the new technology and drugs can certainly help patients to certain degree. However, about 30% RA patients is not responsible for targeting treatment or serious side effects, such as bone marrow inhibition, organs dysfunction, and inflection due to immune inhibition. Research data showed that therapeutic mesenchymal stem cells (MSCs), is a novel therapeutic strategy with safety and effective to inhibit inflammation and promote regeneration of bone and cartilage, especially for refractory RA. Here, the author summarized the development MSC-based treatment for RA models and patients, analysis the optimistic outlook and possible difficulties for clinical applications in future.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
